Advertisement
Advertisement
U.S. markets close in 1 hour 17 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Ionis Pharmaceuticals, Inc. (IONS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
29.94-0.16 (-0.53%)
As of 2:42PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close30.10
Open30.17
Bid29.91 x 900
Ask29.95 x 1100
Day's Range29.84 - 30.60
52 Week Range29.01 - 64.37
Volume291,649
Avg. Volume918,401
Market Cap4.226B
Beta (5Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)-3.97
Earnings DateNov 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.94
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IONS

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ionis Pharmaceuticals, Inc.
    Analyst Report: Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
    Rating
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more
Advertisement
Advertisement